Progress in the field of precision medicine has changed the landscape of cancer therapy.
Precision medicine is propelled by technologies that enable molecular profiling, genomic …

Deregulation of kinase activity has emerged as a major mechanism by which cancer cells
evade normal physiological constraints on growth and survival. To date, 11 kinase inhibitors …

Background The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-
ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …

The truncated chromosome 22 that results from the reciprocal translocation t (9; 22)(q34;
q11) is known as the Philadelphia chromosome (Ph) and is a hallmark of chronic myeloid …

Disruption of the normal regulation of cell-cycle progression and division lies at the heart of
the events leading to cancer. Complex networks of regulatory factors, the tumour …

Imatinib therapy, which targets the oncogene product BCR-ABL, has transformed chronic
myeloid leukemia (CML) from a life-threatening disease into a chronic condition. Most …

The introduction in 1998 of imatinib mesylate (IM) revolutionized management of patients
with chronic myeloid leukemia (CML) and the second generation of tyrosine kinase …

The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic
myeloid leukemia (CML). Although experience is too limited to permit evidence-based …

Clinical oncology is being revolutionized by the increasing use of molecularly targeted
therapies. This paradigm holds great promise for improving cancer treatment; however …

The clinical success of the ABL tyrosine kinase inhibitor imatinib in chronic myeloid
leukaemia (CML) serves as a model for molecularly targeted therapy of cancer,,,, but at least …